Table II.
Characteristic | Median SUVmax (IQR) | P-value |
---|---|---|
ER | ||
Negative | 9.6 (4.0) | 0.004a,c |
Positive | 6 (6.2) | |
PgR | ||
Negative | 9.8 (3.3) | 0.008a,c |
Positive | 6 (6.1) | |
ER Allred score | ||
<4 | 9.2 (3.6) | 0.01a,c |
≥4 | 6 (6.3) | |
PgR Allred score | ||
<4 | 9.1 (4.2) | 0.03a,c |
≥4 | 5.9 (6.1) | |
HER-2 | ||
Negative | 5.7 (6.6) | 0.07a |
Positive | 7.9 (3.8) | |
Triple-negative | ||
Non-TN | 6.8 (5.9) | 0.04a,c |
TN | 10.1 (3.6) | |
Ki-67 | ||
≤10% | 4.7 (6.8) | 0.01a,c |
>10% | 7.8 (5.5) | |
HIF-1α | ||
Negative | 6.0 (6.0) | 0.28a |
Positive | 7.8 (5.5) | |
Grade | ||
1–2 | 5.7 (5.8) | 0.001a,c |
3 | 9.6 (4.1) | |
Tumor size | ||
T1 | 4.8 (3.7) | 0.02b,c,d |
T2 | 7.8 (6.2) | |
T3 | 7.9 (3.8) |
Mann-Whitney U test
Kruskal Wallis test
P<0.05
SUVmax value of T1 is different from SUVmax value of T2 and T3. SUVmax, maximum standardized uptake value; IQR, interquartile range; ER, estrogen receptor; PgR, progesterone receptor; HER-2, human epidermal growth factor receptor-2; HIF-1α, hypoxia induciblefactor-1α.